Blood plasma offers a life-changing treatment to seriously ill patients. The salts, water, enzymes, antibodies, proteins, clotting factors and immunoglobulins extracted from the plasma after blood donation can treat a staggering number of health problems, and it’s this factor that’s prompting considerable growth within the market. With this growth comes bountiful opportunities for companies to assert themselves – as we will be exploring below.
Valued at $31.4 billion in 2021, BCC Research forecasts the market to grow at a compound annual growth rate (CAGR) of 6.6% to reach $45.7 billion by 2027. Let’s explore the emerging opportunities for blood plasma product manufacturers.
Numerous plasma product manufacturers are focusing on enhancing their plasma collection and fractionation capabilities. Business expansions, opening R&D facilities and acquiring new facilities are all actions being explored by manufacturers, which is creating significant opportunities in the market. For example, in late 2022, biotech company CSL opened a new $900 million plasma fractionation facility in Australia. The new facility allows CSL to process up to 9.2 million plasma equivalent liters per year, a nine-fold increase in its current capacity from the site. In September 2022, Takeda announced plans to invest nearly $300 million to construct a new production facility and a warehouse for plasma-derived therapies in Belgium. That’s not all: In July 2021, Grifols signed an agreement with ImmunoTek to open 21 plasma centers for business expansion. The companies plan to complete the construction and begin operations of the 21 plants by October 2022. These expansions are allowing companies to increase their plasma processing and product manufacturing capabilities, spelling out good news for the market.